Compare Wheaton Precious Metals Corp (WPM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wheaton Precious Metals Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Wheaton Precious Metals Corp trades at $135.43 (market cap $60.94B), while State Street SPDR S&P Biotech ETF trades at $159.27. The key difference: Wheaton Precious Metals Corp pays a 0.58% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wheaton Precious Metals Corp nearer its low. Which is the better fit depends on your goals.
| WPM | XBI | |
|---|---|---|
Market Cap | $60.94B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $165.72 | $164.28 |
52-Week Low | $91.02 | $86.92 |
Enterprise Value | $62.82B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wheaton Precious Metals (WPM) trades at $135.51, up 1.59% on the day, reflecting strong momentum amid record financial performance. The stock exhibits a bullish technical trend, supported by consecutive earnings beats and robust cash flow growth. Recent results highlight significant revenue and profit expansion, driven by higher metal prices and increased sales volumes. Analyst sentiment remains overwhelmingly positive, with a consensus Buy rating and a price target implying substantial upside potential.
The outlook for WPM is favorable, underpinned by its high-margin streaming model and exposure to rising precious metal prices. Key opportunities include sustained earnings growth and strategic deal capacity, while risks involve commodity price volatility and execution of future streaming agreements. The stock's current valuation multiples suggest premium pricing, requiring continued operational excellence to justify further appreciation.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
